Neurona Therapeutics to Present at Upcoming Investor Conferences
核心洞察
Neurona Therapeutics (搜索) will participate in William Blair's Innovator Series on October 3, presenting their advancements in regenerative cell therapies.
The company will also attend the Leerink Partners Biopharma Private Company Connect for investor meetings on October 22-23.
Neurona's lead candidate, NRTX-1001, is currently in Phase 1/2 trials for drug-resistant epilepsy (搜索), holding promise for long-term nervous system repair.
Neurona Therapeutics (搜索), a clinical-stage biotherapeutics company focused on regenerative cell therapies for nervous system disorders, announced that CEO Cory R. Nicholas, Ph.D., will participate in two upcoming investor conferences in October. These events will provide an opportunity for Neurona to highlight its progress in developing allogeneic cell therapies, particularly its lead product candidate, NRTX-1001, currently in Phase 1/2 trials for drug-resistant epilepsy (搜索).
Conference Participation
Dr. Nicholas will participate in a fireside chat at the 2024 William Blair’s Innovator Series: Private Biotechnology Stars on Thursday, October 3, at 6:00 am PT / 8:00 am CT. Additionally, Neurona will engage in 1x1 investor meetings at the Leerink Partners Biopharma Private Company Connect on Tuesday, October 22, and Wednesday, October 23.
A replay of the William Blair fireside chat will be available on Neurona's website for seven days following the event.
NRTX-1001: A Novel Cell Therapy for Epilepsy
NRTX-1001, Neurona's lead product candidate, is an allogeneic, off-the-shelf regenerative neural cell therapy designed for long-term targeted repair of the nervous system after a single administration. It comprises GABAergic interneurons (搜索) and is being evaluated in two ongoing open-label, multicenter Phase 1/2 trials (NCT05135091 and NCT06422923) for drug-resistant mesial temporal lobe epilepsy (搜索) (MTLE). One trial focuses on unilateral MTLE, and the other on bilateral MTLE. The company also plans to explore NRTX-1001 for neocortical focal epilepsy and other indications.
The Phase 1 portion of the unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM). In June 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 based on positive clinical data from the ongoing Phase 1/2 trial in unilateral MTLE. The most recent data update was presented at the American Academy of Neurology Annual Meeting in April 2024. In February 2024, Neurona raised $120 million in a private financing co-led by Viking Global Investors and Cormorant Asset Management, signaling strong investor confidence in the company's approach.
About Neurona Therapeutics
Neurona Therapeutics (搜索) is committed to developing regenerative neural cell therapy products with the potential to provide long-term targeted repair of the nervous system following a single administration. The company's focus on allogeneic, off-the-shelf therapies aims to address significant unmet needs in neurological disorders.